Skip to main content
Premium Trial:

Request an Annual Quote

Canopy Biosciences Acquires Biopharma Services Firm Core Diagnostics

NEW YORK — Canopy Biosciences said today it has acquired biopharma services firm Core Diagnostics.

With the purchase, St. Louis, Missouri-based Canopy acquires Core's CLIA facility, from which it will provide its multi-omic immune profiling services.

Core also offers NanoString transcriptional profiling and histopathology services including immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH).

"By combining multi-omic technologies such as chip cytometry, NanoString, and RareSeq, we are building a unique and powerful platform for immune profiling of cells and tissues," Edward Weinstein, Canopy's president and CEO, said in a statement. "Through the addition of Core Diagnostics, this innovative multi-omics platform will now be available to customers in the clinical space in addition to the preclinical and translational customers we already work with."

The acquisition follows Canopy's buy in April of German cytometry firm Zellkraftwerk.

Both acquisitions were made possible by investment from Ampersand Capital Partners.

Financial and other terms of the deal were not disclosed.